Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 527-540

  Arts, Eric J ^a,b   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTIVIRUS AGENT; CARBOVIR; CD4 ANTIGEN; DIDANOSINE; DNA POLYMERASE; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SHORT SURVEY; VIRUS INHIBITION;

EID: 0029912274     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.527     Document Type: Short Survey

References (184)

1. Abbotts, J., K. Bebenek, T. A. Kunkel, and S. H Wilson. 1993. Mechanism of HIV-1 reverse transcriptasc: termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem. J. Biol. Chem. 268:10312-10323.
2. Allain, B., M. Lapadat-Tapolsky, C. Berlioz, and J.-L. Darlix. 1994 Trans-activation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome. EMBO J. 13:973-981.
3. Arts, E. J., X. Li, Z. Gu, L, Kleiman, M. Parniak, and M. A. Wainberg. 1994. Comparison of deoxyoligonucleotide and tRNALys-3 as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/ template-switching reaction. J. Biol. Chem. 269:14672-14680
4. Arts, E. J., Z. Li, and M. A. Wainberg. 1995. Analysis of primer extension and the first template switch during human immunodeficiency virus reverse transcription. J. Biomed. Sci. 2:314-321
5. Arts, E. J., J.-P. Marois, Z. Gu, S. F. J. Le Grice, and M. A. Wainberg. 1996. Effects of 3′-deoxynucleoside 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70:712-720.
6. Arts, E. J., and M. A. Wainberg. 1994. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 38:1008-1016.
7. Bakhanashvili, M., and A. Hizi. 1993. The fidelity of the reverse transcriptases of human immunodeficiency viruses and murine leukemia virus, exhibited by the mispair extension frequencies, is sequence dependent and enzyme related. FEBS Lett 319:201-205
8. Balzarini, J., P. Herdewijn, and E. De Clerk. 1989. Differential patterns of intracellular metabolism of 2′.3′-dihydro-2′.3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine. two potent anti-human immunodeficiency virus compounds J. Biol. Chem. 264:6127-6133.
9. Balzarini, J., A. Karlson, M.-J. Perez-Perez, L. Vrang, J. Walbers, H. Zhang, B. Oberg, A.-M. Vandamme, M.-J. Camarasa, and E. De Clercq. 1993. HIV-1 specific reverse transcriptase inhibitors show differential activity against nHIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253
10. Basu, A., R. S. Tirumalai, and M. J. Modak. 1989. Substrate binding in human immunodeficiency virus reverse transcriptasc. An analysis of pyridoxal 5′-phosphate sensitivity and identification of lysine 263 in the sub-strate-binding domain. J Biol. Chem. 264:8746-8752.
11. Beard, W. A., S. J. Stahl, H.-R. Kim, K. Bebenek, A. Kumar, M.-P. Strub, S. P. Becerra, T. A. Kunkel, and S. H. Wilson. 1994. Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an α-helix in the thumb subdomam. J. Biol Chem. 269:28091-28097
12. Bebenek, K., J. Abbotts, S. H. Wilson, and T. A. Kunkel. 1993. Error-prone polymerization by HIV-1 reverse transcriptase: contribution of template-primer misalignment, miscoding and termination probability to mutational hot spots. J. Biol. Chem 268:10324-10334
13. Bebenek, K., J. D. Roberts, and T. A. Kunkel. 1992 The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J. Biol. Chem. 267:3589-3596.
14. Bianchi, V., E. Pontis, and P. Reichard. 1986. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. 261:16037-16042.
15. Boulerice, F., S. Bour, R. Geleziunas, A. Lvovich, and M. A. Wainberg. 1990. High frequencey of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U937 cells. J. Virol 64:1745-1755.
16. Boyer, J. C., K. Bebenek, and T. A. Kunkel. 1992. Unequal human immunodeficiency virus type 1 reverse transcriptase error rates with RNA and DNA templates. Proc. Natl. Acad. Sci. USA 89:6919-6923.
17. Boyer, P. L., A. L. Ferris, and S. H. Hughes. 1992. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 66:1031-1039.
18. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994 Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleosides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad Sci. USA 91:4882-4886
19. Buckheit, R. W., J. Germany-Decker, K. Qualls-Goodwin, B. J. Bowden, and W. H. Shannon. 1992 3′-Azido-2′-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation. Proc. Natl. Acad. Sci. USA 89:8361-8365.
20. Carroll, S. S., J. Geib, D. O. Olsen, M. Stahlhut, J. A. Schafer, and L. C. Kuo. 1994 Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 33:2113-2120
21. Chaisson, R. E., J.-P. Allain, M. Leuther, and P. A. Volderding. 1986. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N. Engl. J. Med. 315:1610-1611
22. Cheng, N., B. M. Merril, G. R. Painter, L. W. Frick, and P. A. Furman. 1993. Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label. Biochemistry 32:7630-7634.
23. Cheng, Y.-C., G. E. Dutchman, M. K. Bastow, M. G. Sarngadharan, and R. Y. C. Ting. 1987. Human immunodeficiency virus reverse transcriptase: general properties and its interaction with nucleoside triphosphate analogs. J. Biol. Chem. 262:2187-2189.
24. Cherrington, J. M., S. J. Allen, B. H. McKee, and M. S. Chen. 1994. Kinetic analysis of the interaction between the diphosphate of (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP. AZTTP. and FIAUTP with human DNA polymerases β and γ. Biochem Pharmacol. 48:1986-1988
25. Chong, K. T., P. J. Pagano, and R. R. Hinshaw. 1994. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythmidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:288-293.
26. Coates, J. A. V., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vivo Antimicrob. Agents Chemother 36:733-739.
27. Coates, J. A., V. N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992 The separate enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205.
28. Coffin, J. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis. and therapy. Science 267:483-489.
29. Cohen, A., J. Barankiewicz, H. M. Lederman, and E. W. Gelfand. 1983. Purine and pyrimidine metabolism in human lymphocytes Regulation of deoxyribonucleotide metabolism. J Biol. Chem 258:12334-12340.
30. Connolly, K. J., and S. M. Hammer. 1992. Antiretroviral therapy, reverse transcriptase inhibition. Antimicrob. Agents Chemother. 36:245-254.
31. Cox, S. 1992. Metabolism of 3′-azido-3′-deoxythymidine and 3′-fluoro-3′-deoxythymidine in combination in human immunodeficiency virus infected lymphoblastoid cells. Antiviral Chem, Chemother 3:165-170.
32. Dahdo, Y., and S, Eriksson. 1985. On the mechanism of deoxyribonucleoside toxicity in human T-lymphoblastoid cells Reversal of growth inhibition by addition of cytidine. Eur. J. Biochem. 150:429-434.
33. Dahlberg, J. E., H. Mitsuya, S. B. Blam, S. Broder, and S. A. Aaronson. 1987 Broad spectrum antiretroviral activity of 2′,3′-dideoxynucleosides. Proc Natl. Acad Sci. USA 84:2469-2473.
34. D'Aquila, R. T., V. A. Johnson, S. L. Welles, A. J. Japour, D. R. Kuritzkes, V. DeGruttola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn, and D. D. Richman. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
35. De Wolf, F., J. M. A. Lange, J. Goudsmit, P. Cload, J. de Gans, P. T. A. Schellekens, R. A. Coutinho, A. P. Fiddian, and J. Van Der Noordaa. 1988. Effect of Zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet i:373-376.
36. Dornsife, R. E., M. H. St. Clair, A. T. Huang, T. J. Panella, G. W. Koszalka, C. L. Burns, and D. R. Averett. 1991 Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells Antimicrob Agents Chemother. 35:322-328.
37. Dueweke, T. J., F. J. Kezdy, G. A. Waszak, M. R. Deibel, and W. G. Tarpley. 1992. The binding of a novel bisheteroaryliperazinc mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol. Chem. 267:27-30
38. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)pipcrazine-resistant human immunodeficiency virus type 1 confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4712-4717.
39. El-Deiry, W. S., K. M. Downey, and A. G. So. 1984. Molecular mechanisms of manganese mutagenesis. Proc. Natl. Acad Sci. USA 81:7378-7382.
40. Eron, J. J., V. A. Johnson, D. P. Merill, T. C. Chou, and M. S. Hirsh. 1992. Syncrgistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother 36:1559-1562
41. Faraj, A., L. A, Agrofoglio, J. K. Wakfield, S. McPherson, C. D. Morrow, G. Gosselin, C. Mathe, J.-L, Imbach, R. F. Schinazi, and J.-P. Sommadossi, 1994. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs. Antimicrob Agents Chemother. 38:2300-2305.
42. Fischl, M., J. E. Galpin, J. D. Levine, J. E. Groopman, D. H. Henry, P. Kennedy, S. Miles, W. Robbins, B. Starrett, R. Zalusky, R. I. Abels, H. C. Tsai, and S. A. Rudnick. 1990. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl J. Med. 322:1488-1493
43. Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsh, G. G. Jackson, D. T. Drack, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J Med 317:185-191.
44. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, D. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother 36:153-157.
45. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. Nusinoff-Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl. Acad. Sci. USA 83:8333-8337.
46. Furman, P. A., G. Painter, J. E. Wilson, N. Cheng, and S. Hopkins. 1991. Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl Acad. Sci. USA 88:6013-6017.
47. Gao, Q., Z. Gu, J. M. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxycytidine confers highlevel resistance against the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392
48. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol 66:12-19.
49. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes a strategy to inhibit human immunodeficiency virus type 1 replication Proc. Natl. Acad. Sci. USA 90:8925-8928.
50. Gao, W.-Y., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydrourea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:767-772
51. Gao, W.-Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993 Differential phosphorylation of azidothymidine, dideoxycytidine and didcoymosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest 91:2326-2333.
52. Geleziunas, R., E. J. Arts, F. Boulerice, H. Goldman, and M. A. Wainberg. 1993. Effect of 3′-azido-3′-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages. Antimicrob. Agents Chemother. 37:1305-1319.
53. Geleziunas, R., H. M. Schipper, and M. A. Wainberg. 1992. Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS 6:1411-1426.
54. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. Quitero, W. A. Schleif, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991. Pyridinone derivatives specific human immunodeficiency virus type reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88: 6863-6867.
55. Goldman, M. E., J. A. O'Brien, T. L. Ruffing, W. A. Schleif, V. V. Sardana, V. W. Byrnes, J. H. Condra, J. M. Hoffman, and E. A. Emini. 1993. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors. Antimicrob. Agents Chemother. 37:947-949.
56. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-didcoxycytidine 5′-triphosphates and other drugs Proc. Natl Acad Sci. USA 92:1760-2764
57. Gu, Z., R. Fletcher, E. J. Arts, M. A. Wainberg, and M. Parniak. 1994 The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-didcoxycytidine. 2′,3′-dideoxy-3′-thiacytidine. and 2′,3′-didcoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro J. Biol. Chem. 269:28118-28122.
58. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′.3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
59. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992 Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross-resistance to 2′,3′-dideoxyinosine and 2′.3′-dideoxycytidine. J. Virol. 66:7128-7135.
60. Gupta, P., R. Balachandran, M. Ho, A. Enrico, and C. Rinaldo. 1989 Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibodies J. Virol. 63:2361-2365
61. Hammamoto, Y., H. Nakashima, T. Matsui, A. Matsuda, T. Ueda, and N. Yamamoto. 1987. Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob. Agents Chemother. 31:907-910.
62. Hao, Z., D. A. Cooney, N. R. Hartman. C. F. Perno, A. Fridland, A. L. Devico, M. G. Sarngadharan, S. Broder, and D. G. Johns. 1988 Factors determining the activity of 2′,3′-didcoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol. Pharmacol. 34:431-435
63. Harmenberg, J., A. Akesson-Johansson, L. Vrang, and S. Cox. 1990 Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3′-azido-3′ deoxythymidine and 3′-fluoro-3′-deoxythymidine AIDS Res Hum Retroviruses 6:1197-1202
64. Harrington, J. A., J. E. Reardon, and T. Specter. 1993. 3′-Azido-3′-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob. Agents Chemother. 37:918-920.
65. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694
66. Heidenreich, O., M. Kruhoffer, F. Grosse, and F. Eckstein. 1990. Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3′-azidothymidine triphosphate. Eur. J. Biochem. 192:621-625
67. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Mardowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
68. Ho, H.-T., and M. J. M. Hitchcock. 1989. Cellular pharmacology of 2′,3′-dideoxy-2′.3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:844-849
69. Hsieh, J.-C., S. Zinnen, and P. Modrich. 1993. Kinetic mechanism of DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol Chem. 268:24607-24613.
70. Huang, P., D. Farquhar, and W. Plunkett. 1990. Selective action of 3′-azido-3′-deoxythymidine 5′-triphoshate on viral reverse transcriptases and human DNA polymerases. J. Biol. Chem. 265:11914-11918.
71. Huber, H. E., J. M. McCoy, J. S. Seehra, and C. C. Richarson. 1989. Human immunodeficiency virus 1 reverse transcriptase. template binding, processivity, strand displacement synthesis, and template switching. J. Biol Chem. 264:4669-4678.
72. Izuta, S., M. Saneyoshi, T. Sakurai, M. Suzuki, K. Kojima, and S. Yoshida. 1991. The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′.3′-dideoxynucleosides inhibit DNA polymerase γ by different mechanisms. Biochem. Biophys Res. Commun. 179:776-782.
73. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., S. Lu, C. Tantillo, R, L. Williams, G. Kamer, A. L. Fernis, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
74. Jacques, P. S., B. M. Wohrl, M. Ottman, J.-L. Darlix, and S. F. J. LeGrice. 1994. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan 229 in template-primer utilization. J. Biol Chem. 269: 26472-26478.
75. Johnson, M. A., G. Ahluwalia, M. C. Connelly, D. A. Cooney, S. Broder, D. G. Johns, and A. Fridland. 1988. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells J. Biol. Chem. 263:15354-15357.
76. Johnson, M. A., and A. Fridland. 1989. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lympoid cells. Mol. Pharmacol. 36:291-295.
77. Karlsson, A., P. Reichard, and F. Eckstein. 1989. Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells. Eur. J. Biochem. 186:689-694.
78. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997
79. Kellam, P., C. A. B. Boucher, and B. A, Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci USA 89:1934-1938.
80. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
81. Klarmann, G. J., C. A. Schauber, and B. D. Preston. 1993. Templatedirected pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences, in vitro J. Biol. Chem. 268:9793-9802.
82. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256:1783-1790.
83. Kong, X.-B., Q.-Y. Zhu, R. M. Ruprecht, K. A. Watannabe, J. M. Zeidler, J. W. M. Gold, B. Polsky, D. Armstrong, and T.-C. Chou. 1991. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3′-azido-3′-deoxythymidine, phosphonoformate. and 2′,3′-dideoxythymidine. Antimicrob. Agents Chemother. 35:2003-2011.
84. Krieg, C. J., W. Ostertag, U. Clauss, I. B. Pragnell, P. Swetly, G. Roesler, and B. J. Weimann. 1978. Increase in intracisternal A-type particles in Friend cells during inhibition of Friend virus (SFFV) release by interferon or azidothymidine. Exp Cell Res 116:21-29.
85. Kunz, B. A. 1988. Mutagenesis and deoxyribonucleotide pool imbalances. Mutat Res. 200:133-147
86. Lacey, S. F., and B. A. Larder. 1994 Novel mutation (V75T) in human immundeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′.3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
87. Lacey, S. F., J. E. Reardon, E. S. Furfine, T. A. Kunkel, K. Bebenek, K. A. Eckert, S. D. Kemp, and B. A. Larder. 1992. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267:15789-15794.
88. Larder, B., D. J. M. Purifoy, K. Powell, and G. Darby. 1987. Site-specific mutagnesis of AIDS virus reverse transcriptase. Nature (London) 327:716-717.
89. Larder, B. A., K. E. Coates, and S. D. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
90. Larder, B, A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
91. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
92. Larder, B. A, S. D. Kemp, and D. J. M. Purifoy. 1989. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 86:4803-4807.
93. Laskin, O. L., P. de Miranda, and M. R. Blum. 1989. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect. Dis. 159:745-747.
94. Lewis, W., R. R. Meyer, J. F. Simpson, J. M. Colacino, and F. W. Perrino. 1994. Mammalian DNA polymerases α. β. ψ, δ and ε incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 33:14620-14624.
95. Li, P., L. J. Kuiper, A. J. Stephenson, and C. J. Burrell. 1992. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus. J. Gen. Virol. 73:955-959.
96. Lin, P.-F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M. E. Federici, H. Li. A. Lee, R. E. Andersen, and R. J. Colona. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect Dis 170:1157-1164.
97. Lori, F., A. Malykh, A. Cara, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805
98. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother 38:2743-2749.
99. Martin, J. L., J. E. Wilson, E. S. Furfine, S. E. Hopkins, and P. A. Furman. 1993. Biochemical analysis of human immunodeficiency virus-1 reverse transcriptase containing a mutation at position lysine 263. J. Biol Chem 268:2565-2570
100. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Furman. 1993. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA 90:6135-6139.
101. Matthes, E., C. Lehmann, D. Scholz, M. von Janta-Lipinski, K. Gaertner, H. A. Rosenthal, and P. Langen. 1987. Inhibition of HIV-associatcd reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphoshate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res. Commun. 148:78-85.
102. McGowan, J. J., J. E. Tomaszewski, J. Cardock, D. Hoth, C. K. Grieshaber, S. Broder, and H. Mitsuya. 1990. Overview of the preclinical development of an antiretroviral drug. 2′,3′-dideoxyinosine. Rev Infect. Dis. 12(Suppl. 5):S513-S521.
103. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
104. Meyerhans, A., J.-P. Vartanian, C. Hultgren, U. Plikat, A. Karlsson, L. Wang, S. Erikson, and S. Wain-Hobson. 1994. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540
105. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides Proc Natl. Acad. Sci. USA 83:1911-1915.
106. Mitsuya, H., R. F. Jarrett, M. Matsukura, F. Di Marzo Veronese, A. L. DeVico, M. G. Sarngadharan, D. G. Johns, M. S. Reitz, and S. Broder. 1987 Long-term inhibition of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′.3′-dideoxynucleosides in vitro. Proc. Natl. Acad. Sci. USA 84:2033-2037.
107. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R, C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BWA509V): an antiviral agent that inhibits the infectivity and cytopathic effects of human T-lymphotropic virus type III/lymhpadenopathy-associated virus in vitro. Proc. Natl Acad. Sci. USA 82:7096-7100.
108. Mitsuya, H., R. Yarchoan, S. Kageyama, and S. Broder. 1991 Targeted therapy of human immunodeficiency virus-related disease. FASEB J 5:2369-2381.
109. Montaner, J. S. G., J. Singer, M. T. Schechter, J. M. Raboud, C. Tsoukas, M. O'Shaughnessy, J. Ruedy, K. Nagai, H. Salomon, B. Spira, and M. A. Wainberg. 1993. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 7:189-196.
110. Nakashima, H., T. Matsui, S. Harada, N. Kobayashi, A. Matsuda. T. Veda, and N. Yamamoto. 1986. Inhibition of replication and cytopathic effect of human T-cell lymphotrophic virus type III/lymphadenopathy virus by 3′-azido-3′-deoxythymidine in vitro. Antimicrob. Agents Chemother. 30:933-937.
111. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
112. O'Brien, W. A., A. Nazami, H. Kalhor, S. H. Hao, J. A. Zack, and I. S. Y. Chen. 1994. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J. Virol. 68:1258-1263.
113. Olsen, J. C. P. Furman, J. A. Fyfe, and R. Swanstrom. 1987 3′-Azido-3′-deoxythymidine inhibits the replication of avian leukosis virus. J. Virol. 61:2800-2806.
114. Ono, K., M. Ogasawara, Y. Iwata, H. Nakane, T. Fujii, K. Sawai, and M. Saneyoshi. 1986 Inhibition of reverse transcriptase activity by 2′,3′-dideoxythymidine 5′-triphosphate and its derivatives modified on the 3′ position Biochem. Biophys. Res. Commun 140:498-507.
115. Orr, D. C., H. T. Figueiredo, C.-L. Mo, C. R. Penn, and J. M. Cameron. 1992. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′,3′-didehydro-2′.3′-dideoxyguanosine triphosphate J. Biol. Chem. 267:4177-4182.
116. Ostertag, W., G. Roesler, C. J. Krieg, J. Kind, T. Cole, T. Crazier, G. Gaedicke, G. Steinheider, N. Kluge, and S. Dubé. 1974. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc. Natl. Acad. Sci. USA 71:4948-4952.
117. Painter, G. R., A. E. Aulabaugh, and C. W. Andrews. 1993. A comparison of the conformations of the 5′-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun. 191:1166-1171.
118. Painter, G. R., L. L. Wright, S. Hopkins, and P. A. Furman. 1991. Initial binding of 2′-deoxynucleoside 5′-triphosphates to human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 266:19362-19368.
119. Pantaleo, G., C. Gnaziosi, F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 368:355-358.
120. Parker, W. B., E. L. White, S. C. Shaddix, L. J. Ross, R. W. Buckheit, Jr, J. M. Germany, J. A. Secrist, R. Vince, and W. M. Shannon. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′ deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine: a novel RNA template for the evaluation of antiretroviral drugs J. Biol. Chem. 266:1754-1762.
121. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. de Clercq, and P. A. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London) 343:470-474.
122. Pauwels, R., J. Balzarinin, D. Schols, M. Baba, J. Desmyter, I. Rosenberg, A. Holy, and E. De Clercq. 1988. Phosphonyl-methoxyethyl pruine derivatives, a new class of anti-human immunodeficiency virus agents. Antimiciob Agents. Chemother. 32:1025-1030.
123. Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 168:1111-1125.
124. Perno, C.-L., R. Yarchoan, D. A. Cooney, N. R. Hartman, D. S. Webb, Z. Hao, H. Mitsuya, D. G. Johns, and S. Broder. 1989. Replication of human immunodeficiency virus in monocytes. granulocyte/macrophage colonystimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′,3′-dideoxythymidine (AZT) and other dideoxynucleosides congeners of thymidine. J. Exp. Med. 169:933-951.
125. Pokholok, D. K., S. O. Gudima, D. S. Yesipov, V. N. Dobynin, V. O. Rechinsky, and S. N. Kochetkov. 1993. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP. FEBS Lett 325:237-241.
126. Prasad, V. R., I. Lowy, T. De Los Santos, L. Chiang, and S. P. Goff. 1991. Isolation and characterization of a dideoxyguanosine triphosphate-resistant HIV-1 reverse transcriptase expressed in bacteria. Proc. Natl Acad. Sci. USA 88:11363-11367.
127. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase Science 242:1168-1171.
128. Que, B. G., K. M. Downey, and A. G. So. 1978. Mechanisms of selective inhibition of 3′ to 5′ exonuclease activity of Escherichiu coli DNA polymerase I by nucleoside 5′-monophosphates. Biochemisty 17:1603-1606.
129. Reardon, J. E. 1992. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31:4473-4479.
130. Reardon, J. E. 1993 Human immunodeficiency virus reverse transcriptase: a kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J. Biol.
131. Reardon, J. E., and W. H. Miller. 1990. Human immunodeficiency virus reverse transcriptase: substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J Biol. Chem 265:20302-20307.
132. Reichard, P. 1993. From RNA to DNA, why so many ribonucleotide reductases? Science 260:1773-1777.
133. Remington, K. M., Y.-Q. Zhu, T. R. Phillips, and T. W. North. 1994. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol. 68:632-637.
134. Ricchetti, M., and H. Buc. 1990. Reverse transcriptase and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J. 9:1583-1593.
135. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretrovtral agents. Antimicrob. Agents Chemother. 37: 1207-1213
136. Richman, D. D., M. A. Fischl, M. H. Grieco, M. S. Gotttieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch. G. G. Jackson, D. T. Durack, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:192-197.
137. Richman, D. D., A. S. Rosenthal, M. Skoog, R. J. Eckner, T.-C. Chao, J. P. Sabo, and V. J. Merluzzi. 1991. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:305-308.
138. Richman, D. D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. HIV-1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci USA 88:11241-11245
139. Romero, D. L., M. Busso, C. K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Non-nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
140. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaugnessy, K. Gelman, C. D. Tsoukas, J. Gill, J. Ruedy, M. A. Wainberg, and the Canadian Zidovudine Multi-Centre Study Group. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 3:411-115.
141. Rooke, R., M. Tremblay, and M. A. Wainberg. 1990. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology 176:205-215.
142. Rozencweig, M., C. McLaren, M. Beltangody, J. Ritter, R. Canetta, L. Schacter, S. Kelly, C. Nicaise, L. Smaldone, L Dunkle, R. Barbhaiya, C. Knupp, A. Cross, M. Tsianco, and R. R. Martin. 1990. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. Infect. Dis. 12:S570-S575.
143. Sardana, V. V., E. A. Emini, L. Gotlib, D. J. Graham, D. W. Lineberger, W. J. Long, A. J. Schlabach, J. A. Wolfgang, and J. H. Condra. 1992. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors. J Biol. Chem. 267:17526-17530.
144. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L.-S. Jeong, J. W. Beach, W.-B. Choi, S. Yeola, and D. C. Liotta. 1992. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676.
145. Schinazi, R. F., R, M. Lloyd, M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
146. Schinazi, R. F., A. McMillan, D. Cannon, R. Mathis, R. M. Lloyd, A. Peck, J. P. Sommadossi, M. St. Clair, J. Wilson, P. A. Furman, G. Painter, W. B. Choi, and D. C. Liotta. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxanthiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431.
147. Shih, C.-K., J. M. Rose, G. L. Hansen, J. C. Wu, A. Bacolla, and J. A. Griffin. 1991. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptase display reversed sensitivity to nonnucleoside analog inhibitors Proc. Natl. Acad Sci USA 88:9878-9882
148. Smerdon, S. J., J. Jager, J. Wang, L. A. Kohlstaedt, A. J. Chirino, J. M. Fried man, P. A. Rice, and T. A. Steitz. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 91:3911-3915.
149. Smith, M. S., E. L. Brian, and J. S. Pangano. 1987. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol. 61:3769-3773.
150. Smith, M. S., J. A. Kessler, C. D. Rankin, J. S. Pagano, J. Kurtzberg, and S. G. Carter. 1993. Evaluation of synergy between carbovir and 3′-azido-2′,3′-deoxythymidine for inhibition of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37:144-147.
151. Sommadossi, J.-P., R. Carlisle, R. F. Schinazi, and Z. Zhou. 1988. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity Antimicrob. Agents Chemother. 32:997-1001.
152. Soudeyns, H., X.-Y. Yao, Q. Gao, B. Belleau, J.-L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. 1991 Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocychc nucleoside analog. Antimicrob. Agents Chemother. 35:1386-1390.
153. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991 Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase Science 253:1557-1559.
154. St. Clair, M. H., C. A. Richards, T. Spector, K. J. Weinhold, W. H. Miller, A. J. Langlois, and P. A. Furman. 1987. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase Antimicrob Agents Chemother. 31:1972-1977.
155. St. Luce, S., E. Arts, R. Geleziunas, S. Bour, and M. A. Wainberg. 1993. Infection of human monocyte-derived macrophages by cell-to-cell transmission J. Med. Virol. 41:71-78.
156. Szenbeni, J., S. S. Patel, K. Hung, S. H. Wahl, and J. N. Weinstein. 1991 Effects of thymidine and undine on the phosphorylation of 3′-azido-3′-deoxythymidine (zidovudine) in human mononuclear cells Antimicrob. Agents Chemother. 35:198-200.
157. Szebeni, J., S. M. Wahl, M. Popovic, L. M. Wahl, S. Gartner, R. L. Fine, U. Skaleric, R. M. Friedman, and J. N. Weinstein. 1989. Dipyridamole potentiates the inhibition by 3′-azido-3′-decoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc. Natl. Acad Sci. USA 86:3842-3846.
158. Tan, C.-K., R. Civil, A. M. Mian, A. G. So, and K. M. Downey. 1991. Inhibition of the RNase H activity of HIV reverse transcriptase by azido-thymidylate. Biochemistry 30:4831-4835.
159. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. And ries, P. A. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. Mol. Biol 243:369-387.
160. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl Acad Sci. USA 90:5653-5056.
161. Tsai, C-H., S.-L. Doong, D. G. Johns, J. S. Driscoll, and Y.-C. Cheng, 1994. Effect of anti-HIV 2′-b-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem, Pharmacol. 48:1477-1481.
162. Tsuchihashi, Z., and P. O. Brown. 1994. DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. J Virol 68:5863-5870.
163. Vartanian, J. P., A. Meyerans, M. Sala, and S. Wain-Hobson. 1994. G to A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 91:3092-3096.
164. Vince, R., M. Hua, J. Brownell, S. Daluge, F. Lee, W. M. Shannon, G. C. Lavelle, J. Quails, O. S. Weislow, P. Kiser, P. G. Canonico, R. H. Schultz, V. L. Narayanan, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd. 1988. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir. NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 156:1046-1053.
165. Volberding, P. A., S. W. Lagoakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, D. H. Balfour, R. C. Reichman, J. A. Bartlett, M. S. Hirsch, R. L, Murphy, W. D. Hardy, R. Soiero, M. A. Fischl, J. G. Bartlett, T. C. Merigan, N. E. Hyslop, D. D. Richman, F. T. Valentine, L. Corey, and AIDS Clinical Trial Group. 1990. Zidovudine in asymptomatic human immunodeficiency virus infections A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322:941-949.
166. Wainberg, M. A., Z. Gu, Q. Gao, E. Arts, R. Geleziunas, S. Bour, R. Beaulieu, C. Tsoukas, J. Singer, and J. Montaner. 1993. Clinical correlates and molecular basis of HIV drug resistance. J. Acquired Immune Defic. Syndr. 6(Suppl. 1):S36-S46
167. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992 In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.
168. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.
169. West, A. B., T. M. Roberts, and R. D. Kolodner. 1992. Regulation of the reverse transcriptase of human immunodeficiency virus type 1 by dNTPs Proc. Natl. Acad Sci. USA 89:9720-9724.
170. White, E. L., W. B. Parker, S. J. Macy, S. C. Shaddix. G. McCaleb, J. A. Secrist, R. Vince. and W. M. Shannon. 1989. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases Biochem. Biophys Res. Commun 161:393-398.
171. White, E. L., W. B. Parker, S.J. Ross, and W. M. Shannon. 1993. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antiviral Res. 22:295-308.
172. Wilson, J. E., J. L. Martin, K. Borroto-Esoda, S. Hopkins, G, Painter, D. C. Liotta, and P. A. Furman. 1993. The 5′-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl] cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother 37:1720-1722.
173. Wu, J., E. Amandoron, X. Li, M. A. Wainberg, and M. A. Parniak, 1993. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. J. Biol. Chem 268:9980-9985.
174. Wu, J. C., T. C. Warren, J. Adams, J. Proudfoot, J. Skiles, P. Raghaven, C. Perry, I. Potocki, P. R. Farina, and P. M. Grop. 1991. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 30:2022-2026.
175. Yarchoan, R., R. W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lylerly, D. T. Durak, E. Gelman, S. N. Lehrman, R. M. Blum, D. W. Barry, G. M. Shearer, M. A. Fischl, H. Mitsuya, S. C. Gallo, J. M. Collons, D. P. Bolognesi, C. E. Myers, and S. Broder. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex Lancet i:575-580.
176. Yarchoan, R., H. Mitsuya, C. E. Mycrs, and S. Broder. 1989. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine(zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321:726-738.
177. Yarchoan, R., H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman, C. F. Perno, K. S. Marczyk, J. P. Allain, D. G. Johns, and S. Broder. 1989 In vivo activity against HIV and favourable toxicity profile of 2′,3′-dideoxyinosine. Science 245:412-415.
178. Yarchoan, R., C. F. Perno, R. V. Thomas, R. W. Klecker, J.-P. Allain, J. Willis, N. McAtee, M. A. Fischl, R. Dubinskli, M. C. McNeely, A. Mitsuya, J. M. Pluda, T. J. Lawley, M. Leuther, B. Safai, J. M. Collins, C. E. Myers, and S. Broder. 1988. Phase I studies of 2′,3′-dideoxy-cytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet i:76-81.
179. Yarchoan, R., J. M. Pluda, C.-F. Pernu, H. Mitsuya, and S. Broder. 1991. Antiretroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future Blood 78:859-884.
180. Zack, J. A., S. J. Arrigo, S. R. Weitman, A. S. Go, A. Haislip, and I. S. Y. Chen. 1990 HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure Cell 61:213-222.
181. Zack, J. A., A. M. Haislip, P. Krogstad, and I. S. Chen. 1992. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle J. Virol. 66:1717-1725.
182. Zhan, X., C.-K. Tan, W. A. Scott, A. M. Mian, K. M. Downey, and A. G. So. 1994. Catalytically distant conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azido-thymidylate and N-ethylmaleimide. Biochemistry 33:1366-1372.
183. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.
184. Zimmerman, T. P., W. B, Mahoney, and K. L. Prus. 1987. 3′-Azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:5748-5754